Evidence map›Paper›PMID 35431863›Full record

ArticleCase reports in oncology

BRCA1 Mutation: An Insidious Enemy with Multiple Facets….

Pierrick Godin, Francois P Duhoux, Filomena Mazzeo, Michel Rojas, Emmanuel Bollue, Aline François, Christine Galant, Julien Coulie, Maude Coyette, Audrey Lentini and 5 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Pierrick GodinKing Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
Francois P DuhouxKing Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
Filomena MazzeoKing Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
Michel RojasBreast Clinic, Department of Oncology Centre hospitalier de Mouscron CHM Mouscron, Mouscron, Belgium.
Emmanuel BollueBreast Clinic, Department of Gynaecology, Centre Hospitalier Namur-Mont Godinne, CHU Namur, Namur, Belgium.
Aline FrançoisKing Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
Christine GalantKing Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
Julien CoulieKing Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
Maude CoyetteKing Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
Audrey LentiniKing Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
Yannick DeswisenKing Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
Vasiliki PerlepeKing Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
Latifa FellahKing Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
Isabelle LeconteKing Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
Martine BerlièreKing Albert II Cancer Institute, (Department) Cliniques Universitaires Saint- Luc, Catholic University of Louvain, Brussels, Belgium.
Cliniques Universitaires Saint-Luc · BECentre Hospitalier de Mouscron · BECentre Hospitalier Régional de Namur · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidemiological studies suggest that around 10% of breast cancers are due to hereditary predisposition. The risk of cancer is exponentially increased in patients harboring

Indexed as

AngiosarcomaHereditary breast and ovarian cancerPARP inhibitors

Identifiers

PMID35431863
PMCPMC8958584
OpenAlexW4220819757

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.